BEAM

Beam Therapeutics Inc.

Beam Therapeutics Inc. (BEAM) has 15 SEC Form 4 filings (27 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jul 2, 2026.

The most active filer is CEO Evans John M. with 5 filings. Insiders have net sold $14.3M over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:John Evans
  • Employees:522
  • HQ:Cambridge, MA, US
  • IPO:2020-02-06

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$14.3M

reported sales (SEC code S)

Unique Insiders

6

in the rolling window

Market Cap

$2.6B

latest known value

Source
Sale$13KJul 2SEC ↗
Sale$887KJul 1SEC ↗
Sale$858KJul 1SEC ↗
FMR LLCFirst filing
Sale$1.2MJun 29SEC ↗
FMR LLCFirst filing
Sale$8.9MJun 29SEC ↗
Simon AmyFirst filing
Sale$165KApr 6SEC ↗
Sale$290KApr 6SEC ↗
Bellon ChristineFirst filing
Sale$146KApr 6SEC ↗
Sale$739KApr 6SEC ↗
Cavanagh Bethany JFirst filing
Sale$80KApr 6SEC ↗
Evans John M.First filing
Sale$559KApr 1SEC ↗
Evans John M.First filing
Sale$569KApr 1SEC ↗

Related companies

Beam Therapeutics Inc. is in the Healthcare sector.